MIV-711 Phase Ib Trial Commenced By Medivir Pharma Company

Medivir AB, the research-based drug company centered on the introduction of high-value therapies for infectious diseases, is reporting that a clinical phase Ib trial of the companies candidate drug (CD) MIV-711 has started out.

MIV-711 is a cathepsin K inhibitor meant to treat skeletal problems which has high bone resorption inclusive of osteoporosis, rheumatoid arthritis and bone metastases. Cathepsin K is an element that is vital to the metabolism of bone and cartilage and, accordingly, inhibition of cathepsin K is predicted to have a constructive effect on those conditions.

MIV-711's clinical phase I plan was started in May. Phase Ia was recently finished, wherein increasing single doses were applied to healthy volunteers to assess overall safety, tolerability, pharmacokinetics and performance on biomarkers. The results were usually potentially promising and a phase Ib trial has now set out in which repeated single daily dosages will be administered to teams of healthy volunteers such as post-menopausal women. Overall safety, tolerability, pharmacokinetics and performance on biomarkers will be tested during 7-14 days' therapy.